Double-Edge Sword of Sustained ROCK Activation in Prion Diseases through Neuritogenesis Defects and Prion Accumulation
Transmissible Spongiform Encephalopathies (TSEs), commonly named prion diseases, are caused by deposition in the brain of pathogenic prions PrPSc that trigger massive neuronal death. Because of our poor understanding of the mechanisms sustaining prion-induced neurodegeneration, there is to date no effective medicine to combat TSEs. The current study demonstrates that ROCK kinases are overactivated in prion-infected cells and contribute to prion pathogenesis at two levels. First, PrPSc-induced ROCK overactivation affects neuronal polarity with synapse disconnection, axon/dendrite degradation, and disturbs neuronal functions. Second, ROCK overactivity amplifies the production of pathogenic prions. The pharmacological inhibition of ROCK protects diseased neurons from PrPSc toxicity by preserving neuronal architecture and functions and lowering PrPSc level. Inhibition of ROCK in prion-infected mice reduces brain PrPSc levels, improves motor activity and extends lifespan. This study opens up new avenues to design ROCK-based therapeutic strategies to fight TSEs.
Vyšlo v časopise:
Double-Edge Sword of Sustained ROCK Activation in Prion Diseases through Neuritogenesis Defects and Prion Accumulation. PLoS Pathog 11(8): e32767. doi:10.1371/journal.ppat.1005073
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1005073
Souhrn
Transmissible Spongiform Encephalopathies (TSEs), commonly named prion diseases, are caused by deposition in the brain of pathogenic prions PrPSc that trigger massive neuronal death. Because of our poor understanding of the mechanisms sustaining prion-induced neurodegeneration, there is to date no effective medicine to combat TSEs. The current study demonstrates that ROCK kinases are overactivated in prion-infected cells and contribute to prion pathogenesis at two levels. First, PrPSc-induced ROCK overactivation affects neuronal polarity with synapse disconnection, axon/dendrite degradation, and disturbs neuronal functions. Second, ROCK overactivity amplifies the production of pathogenic prions. The pharmacological inhibition of ROCK protects diseased neurons from PrPSc toxicity by preserving neuronal architecture and functions and lowering PrPSc level. Inhibition of ROCK in prion-infected mice reduces brain PrPSc levels, improves motor activity and extends lifespan. This study opens up new avenues to design ROCK-based therapeutic strategies to fight TSEs.
Zdroje
1. Ferri A, Sanes JR, Coleman MP, Cunningham JM, Kato AC (2003) Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Curr Biol 13: 669–673. 12699624
2. Gillingwater TH, Ingham CA, Coleman MP, Ribchester RR (2003) Ultrastructural correlates of synapse withdrawal at axotomized neuromuscular junctions in mutant and transgenic mice expressing the Wld gene. J Anat 203: 265–276. 14529044
3. Sievers C, Platt N, Perry VH, Coleman MP, Conforti L (2003) Neurites undergoing Wallerian degeneration show an apoptotic-like process with Annexin V positive staining and loss of mitochondrial membrane potential. Neurosci Res 46: 161–169. 12767479
4. Brose N, O'Connor V, Skehel P (2010) Synaptopathy: dysfunction of synaptic function? Biochem Soc Trans 38: 443–444. doi: 10.1042/BST0380443 20298199
5. Aguzzi A, Baumann F, Bremer J (2008) The prion's elusive reason for being. Annu Rev Neurosci 31: 439–477. doi: 10.1146/annurev.neuro.31.060407.125620 18558863
6. Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, et al. (1996) Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379: 339–343. 8552188
7. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, et al. (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302: 871–874. 14593181
8. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, et al. (2005) Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308: 1435–1439. 15933194
9. Harris DA, True HL (2006) New insights into prion structure and toxicity. Neuron 50: 353–357. 16675391
10. Winklhofer KF, Tatzelt J, Haass C (2008) The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J 27: 336–349. doi: 10.1038/sj.emboj.7601930 18216876
11. Rambold AS, Muller V, Ron U, Ben-Tal N, Winklhofer KF, et al. (2008) Stress-protective signalling of prion protein is corrupted by scrapie prions. EMBO J 27: 1974–1984. Epub 2008 Jun 1919. doi: 10.1038/emboj.2008.122 18566584
12. Schneider B, Pietri M, Pradines E, Loubet D, Launay JM, et al. (2011) Understanding the neurospecificity of Prion protein signaling. Front Biosci 16: 169–186.
13. Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, et al. (2008) Physiology of the prion protein. Physiol Rev 88: 673–728. doi: 10.1152/physrev.00007.2007 18391177
14. Alleaume-Butaux A, Dakowski C, Pietri M, Mouillet-Richard S, Launay JM, et al. (2013) Cellular prion protein is required for neuritogenesis: fine-tuning of multiple singaling pathways involved in focal adhesions and actin cytoskeleton dynamics. Cell Health and Cytoskeleton 5: 1–12.
15. Loubet D, Dakowski C, Pietri M, Pradines E, Bernard S, et al. (2012) Neuritogenesis: the prion protein controls beta1 integrin signaling activity. Faseb J 26: 678–690. doi: 10.1096/fj.11-185579 22038049
16. Graner E, Mercadante AF, Zanata SM, Forlenza OV, Cabral AL, et al. (2000) Cellular prion protein binds laminin and mediates neuritogenesis. Brain Res Mol Brain Res 76: 85–92. 10719218
17. Santuccione A, Sytnyk V, Leshchyns'ka I, Schachner M (2005) Prion protein recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite outgrowth. J Cell Biol 169: 341–354. 15851519
18. Lopes MH, Hajj GN, Muras AG, Mancini GL, Castro RM, et al. (2005) Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways. J Neurosci 25: 11330–11339. 16339028
19. Hajj GN, Santos TG, Cook ZS, Martins VR (2009) Developmental expression of prion protein and its ligands stress-inducible protein 1 and vitronectin. J Comp Neurol 517: 371–384. doi: 10.1002/cne.22157 19760599
20. Beraldo FH, Arantes CP, Santos TG, Queiroz NG, Young K, et al. (2010) Role of alpha7 nicotinic acetylcholine receptor in calcium signaling induced by prion protein interaction with stress-inducible protein 1. J Biol Chem 285: 36542–36550. doi: 10.1074/jbc.M110.157263 20837487
21. Beraldo FH, Arantes CP, Santos TG, Machado CF, Roffe M, et al. (2011) Metabotropic glutamate receptors transduce signals for neurite outgrowth after binding of the prion protein to laminin gamma1 chain. Faseb J 25: 265–279. doi: 10.1096/fj.10-161653 20876210
22. Mouillet-Richard S, Mutel V, Loric S, Tournois C, Launay JM, et al. (2000) Regulation by neurotransmitter receptors of serotonergic or catecholaminergic neuronal cell differentiation. J Biol Chem 275: 9186–9192. 10734054
23. Mouillet-Richard S, Nishida N, Pradines E, Laude H, Schneider B, et al. (2008) Prions impair bioaminergic functions through serotonin- or catecholamine-derived neurotoxins in neuronal cells. J Biol Chem 283: 23782–23790. doi: 10.1074/jbc.M802433200 18617522
24. Pietri M, Dakowski C, Hannaoui S, Alleaume-Butaux A, Hernandez-Rapp J, et al. (2013) PDK1 decreases TACE-mediated alpha-secretase activity and promotes disease progression in prion and Alzheimer's diseases. Nat Med 19: 1124–1131. doi: 10.1038/nm.3302 23955714
25. Paquet S, Langevin C, Chapuis J, Jackson GS, Laude H, et al. (2007) Efficient dissemination of prions through preferential transmission to nearby cells. J Gen Virol 88: 706–713. 17251590
26. Bernard O (2007) Lim kinases, regulators of actin dynamics. Int J Biochem Cell Biol 39: 1071–1076. 17188549
27. Endo M, Ohashi K, Sasaki Y, Goshima Y, Niwa R, et al. (2003) Control of growth cone motility and morphology by LIM kinase and Slingshot via phosphorylation and dephosphorylation of cofilin. J Neurosci 23: 2527–2537. 12684437
28. Ng J, Luo L (2004) Rho GTPases regulate axon growth through convergent and divergent signaling pathways. Neuron 44: 779–793. 15572110
29. Riento K, Ridley AJ (2003) Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4: 446–456. 12778124
30. Mueller BK, Mack H, Teusch N (2005) Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 4: 387–398. 15864268
31. Olson MF (2008) Applications for ROCK kinase inhibition. Curr Opin Cell Biol 20: 242–248. doi: 10.1016/j.ceb.2008.01.002 18282695
32. Stankiewicz TR, Linseman DA (2014) Rho family GTPases: key players in neuronal development, neuronal survival, and neurodegeneration. Front Cell Neurosci 8: 314. doi: 10.3389/fncel.2014.00314 25339865
33. Launay JM, Schneider B, Loric S, Da Prada M, Kellermann O (2006) Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. FASEB J 20: 1843–1854. 16940156
34. Peyrin JM, Deleglise B, Saias L, Vignes M, Gougis P, et al. (2011) Axon diodes for the reconstruction of oriented neuronal networks in microfluidic chambers. Lab Chip 11: 3663–3673. doi: 10.1039/c1lc20014c 21922081
35. Deleglise B, Lassus B, Soubeyre V, Alleaume-Butaux A, Hjorth JJ, et al. (2013) Synapto-protective drugs evaluation in reconstructed neuronal network. PLoS One 8: e71103. doi: 10.1371/journal.pone.0071103 23976987
36. Deleglise B, Magnifico S, Duplus E, Vaur P, Soubeyre V, et al. (2014) ss-amyloid induces a dying-back process and remote trans-synaptic alterations in a microfluidic-based reconstructed neuronal network. Acta Neuropathol Commun 2: 145. doi: 10.1186/s40478-014-0145-3 25253021
37. Cronier S, Laude H, Peyrin JM (2004) Prions can infect primary cultured neurons and astrocytes and promote neuronal cell death. Proc Natl Acad Sci U S A 101: 12271–12276. 15302929
38. Cronier S, Beringue V, Bellon A, Peyrin JM, Laude H (2007) Prion strain- and species-dependent effects of antiprion molecules in primary neuronal cultures. J Virol 81: 13794–13800. 17913812
39. Westergard L, Turnbaugh JA, Harris DA (2011) A naturally occurring, C-terminal fragment of the prion protein delays disease and acts as a dominant negative inhibitor of PrPSc formation. J Biol Chem 286: 44234–44242. doi: 10.1074/jbc.M111.286195 22025612
40. Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, et al. (2000) Signal transduction through prion protein. Science 289: 1925–1928. 10988071
41. Calleja V, Laguerre M, de Las Heras-Martinez G, Parker PJ, Requejo-Isidro J, et al. (2014) Acute regulation of PDK1 by a complex interplay of molecular switches. Biochem Soc Trans 42: 1435–1440. doi: 10.1042/BST20140222 25233428
42. Gao X, Harris TK (2006) Role of the PH domain in regulating in vitro autophosphorylation events required for reconstitution of PDK1 catalytic activity. Bioorg Chem 34: 200–223. 16780920
43. Li Y, Yang KJ, Park J (2010) Multiple implications of 3-phosphoinositide-dependent protein kinase 1 in human cancer. World J Biol Chem 1: 239–247. doi: 10.4331/wjbc.v1.i8.239 21537480
44. Vidal C, Herzog C, Haeberle AM, Bombarde C, Miquel MC, et al. (2009) Early dysfunction of central 5-HT system in a murine model of bovine spongiform encephalopathy. Neuroscience 160: 731–743. doi: 10.1016/j.neuroscience.2009.02.072 19285121
45. Da Silva JS, Medina M, Zuliani C, Di Nardo A, Witke W, et al. (2003) RhoA/ROCK regulation of neuritogenesis via profilin IIa-mediated control of actin stability. J Cell Biol 162: 1267–1279. 14517206
46. Bramham CR (2007) Control of synaptic consolidation in the dentate gyrus: mechanisms, functions, and therapeutic implications. Prog Brain Res 163: 453–471. 17765733
47. Kim S, Coulombe PA (2010) Emerging role for the cytoskeleton as an organizer and regulator of translation. Nat Rev Mol Cell Biol 11: 75–81. doi: 10.1038/nrm2818 20027187
48. Jung H, Yoon BC, Holt CE (2012) Axonal mRNA localization and local protein synthesis in nervous system assembly, maintenance and repair. Nat Rev Neurosci 13: 308–324. doi: 10.1038/nrn3210 22498899
49. Howe JG, Hershey JW (1984) Translational initiation factor and ribosome association with the cytoskeletal framework fraction from HeLa cells. Cell 37: 85–93. 6722878
50. Heuijerjans JH, Pieper FR, Ramaekers FC, Timmermans LJ, Kuijpers H, et al. (1989) Association of mRNA and eIF-2 alpha with the cytoskeleton in cells lacking vimentin. Exp Cell Res 181: 317–330. 2466674
51. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O (2010) miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 329: 1537–1541. doi: 10.1126/science.1193692 20847275
52. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, et al. (2012) Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. Nature 485: 507–511. doi: 10.1038/nature11058 22622579
53. Gibson CL, Srivastava K, Sprigg N, Bath PM, Bayraktutan U (2014) Inhibition of Rho-kinase protects cerebral barrier from ischaemia-evoked injury through modulations of endothelial cell oxidative stress and tight junctions. J Neurochem 129: 816–826. doi: 10.1111/jnc.12681 24528233
54. Guo R, Liu B, Zhou S, Zhang B, Xu Y (2013) The protective effect of fasudil on the structure and function of cardiac mitochondria from rats with type 2 diabetes induced by streptozotocin with a high-fat diet is mediated by the attenuation of oxidative stress. Biomed Res Int 2013: 430791. doi: 10.1155/2013/430791 23762845
55. Zhou Y, Su Y, Li B, Liu F, Ryder JW, et al. (2003) Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302: 1215–1217. 14615541
56. Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, Guerra MJ, Labandeira-Garcia JL (2013) Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. Neurobiol Dis 58: 209–219. doi: 10.1016/j.nbd.2013.06.004 23774254
57. Labandeira-Garcia JL, Rodriguez-Perez AI, Villar-Cheda B, Borrajo A, Dominguez-Meijide A, et al. (2014) Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson's Disease. Neuroscientist.
58. Herskowitz JH, Feng Y, Mattheyses AL, Hales CM, Higginbotham LA, et al. (2013) Pharmacologic inhibition of ROCK2 suppresses amyloid-beta production in an Alzheimer's disease mouse model. J Neurosci 33: 19086–19098. doi: 10.1523/JNEUROSCI.2508-13.2013 24305806
59. Pietri M, Caprini A, Mouillet-Richard S, Pradines E, Ermonval M, et al. (2006) Overstimulation of PrPC signaling pathways by prion peptide 106–126 causes oxidative injury of bioaminergic neuronal cells. J Biol Chem 281: 28470–28479. 16864581
60. Lenter M, Uhlig H, Hamann A, Jeno P, Imhof B, et al. (1993) A monoclonal antibody against an activation epitope on mouse integrin chain beta 1 blocks adhesion of lymphocytes to the endothelial integrin alpha 6 beta 1. Proc Natl Acad Sci U S A 90: 9051–9055. 7692444
61. Kempster S, Bate C, Williams A (2007) Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport 18: 479–482. 17496807
62. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL (2005) Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 97: 1808–1815. 16368942
63. Bate C, Langeveld J, Williams A (2004) Manipulation of PrPres production in scrapie-infected neuroblastoma cells. J Neurosci Methods 138: 217–223. 15325130
64. Hofler A, Nichols T, Grant S, Lingardo L, Esposito EA, et al. (2011) Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays. Anal Biochem 414: 179–186. doi: 10.1016/j.ab.2011.03.013 21402045
65. Moore DD, Sefton BM (1997) Analysis of protein phosphorylation. Current Protocols in Molecular Biology (J Wiley & Sons, Inc).
66. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, et al. (1997) 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 7: 776–789. 9368760
67. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, et al. (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. Embo J 15: 6541–6551. 8978681
68. Yadavalli R, Guttmann RP, Seward T, Centers AP, Williamson RA, et al. (2004) Calpain-dependent endoproteolytic cleavage of PrPSc modulates scrapie prion replication. J Biol Chem 279: 21948–56. 15026410
69. Mays CE, Kim C, Haldiman T, van der Merwe J, Lau A, et al. (2014) Prion disease tempo determined by host-dependent substrate reduction. J Clin Invest 124: 847–58. doi: 10.1172/JCI72241 24430187
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2015 Číslo 8
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
- Type VI Secretion System Toxins Horizontally Shared between Marine Bacteria
- Are Human Intestinal Eukaryotes Beneficial or Commensals?
- Illuminating Targets of Bacterial Secretion